Aristides Capital LLC Makes New Investment in Alpha Cognition, Inc. (NASDAQ:ACOG)

Aristides Capital LLC acquired a new stake in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 200,000 shares of the company's stock, valued at approximately $1,178,000. Aristides Capital LLC owned about 1.25% of Alpha Cognition as of its most recent filing with the Securities and Exchange Commission.

Separately, National Bank of Canada FI purchased a new position in shares of Alpha Cognition in the fourth quarter worth approximately $69,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Alpha Cognition in a research report on Monday, March 31st. Raymond James upgraded shares of Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th.

Alpha Cognition Price Performance

Shares of ACOG stock traded up $0.10 on Friday, hitting $4.27. The company's stock had a trading volume of 9,384 shares, compared to its average volume of 81,408. Alpha Cognition, Inc. has a fifty-two week low of $3.75 and a fifty-two week high of $7.00. The firm's fifty day moving average price is $5.48. The firm has a market cap of $68.41 million, a PE ratio of -1.67 and a beta of 2.50.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Alpha Cognition Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.